Key Highlights

  • Epsilon Healthcare (ASX:EPN) traded at A$0.020, down 13.04%.
  • Atomo Diagnostics (ASX:AT1) traded at A$0.013, down 7.14%.
  • Adherium (ASX:ADR) traded at A$0.061, down 8.96%.

Three ASX healthcare companies fell during the Trading session on 5 November 2026, even as the ASX Health Care sector was up 3.08% at midday and the S&P/ASX 200 was up 1.87%. Each company's latest Quarterly Report was released in late October 2026, so none of the price moves is linked to those reports.

Epsilon Healthcare (ASX:EPN): quarterly receipts up 34%

Epsilon shares traded at A$0.020, down 13.04%. Its 30 October 2026 quarterly report showed receipts of A$3.9 million for the September quarter, up 34% year on year, with year-to-date Revenue of A$11.5 million.

Atomo Diagnostics (ASX:AT1): Q1 FY27 revenue of A$1.63 million

Atomo shares traded at A$0.013, down 7.14%. Its 29 October 2026 Q1 FY27 report recorded revenue of A$1.63 million, growth of 140% on the comparable quarter, and cash on hand of A$2.67 million.

Adherium (ASX:ADR): remote patient monitoring revenue

Adherium shares traded at A$0.061, down 8.96%. Its 30 October 2026 quarterly report showed remote patient monitoring revenue of A$539,000, up 12.5% on the prior quarter, and John Perry was appointed Interim Chief Executive Officer.

Final Word

The three companies cover different parts of healthcare, from pharmacy and contract Manufacturing to diagnostics and digital respiratory monitoring. Their quarterly reports describe revenue growth alongside continued investment, and their shares are all low-priced.